Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
May 02 2022 - 7:00AM
Business Wire
- Namodenoson induced complete response and cleared all cancer
lesions in advanced liver cancer patient in Phase II study
- Pivotal Phase III trial for the treatment of liver cancer is
now open for the recruitment of patients
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address inflammatory, cancer and liver
diseases, today announced the Company’s CEO Dr. Pnina Fishman has
been invited as an expert speaker to deliver a presentation titled
“Targeting the A3 Adenosine Receptor for the Treatment of Advanced
Liver Cancer” at the Adenosine Pathway Targeted Cancer
Immunotherapy Summit in Boston on May 12, 2022.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220502005267/en/
Radiological data show the disappearance
of tumor lesions from a patient treated with Namodenoson who had
advanced disease and fully recovered. (Graphic: Business Wire)
Namodenoson, a small orally bioavailable drug that specifically
binds to the A3 adenosine receptor (A3AR), over-expressed in liver
cancer but not normal cells, is headed into a Phase III liver
cancer pivotal trial. The trial has received a green light from
both the U.S. FDA and the European Medicines Agency (EMA) and is
now open for the recruitment of approximately 450 patients
diagnosed with hepatocellular carcinoma (HCC) and underlying Child
Pugh B7 (CPB7) who have not responded to other approved therapies.
A prior Phase II HCC study patient who continues to be treated with
Namodenoson has survived more than five years and cleared all
cancer lesions.
“Adenosine pathway targets have become one of the most
clinically validated oncology pathways, further validating our A3AR
target for the treatment of liver and other cancers. I’m pleased to
be invited to speak and share Can-Fite’s experience with adenosine
pathway drug development and clinical trials, and radiological data
showing the disappearance of tumor lesions from a patient treated
with Namodenoson who had advanced disease and fully recovered,”
stated Can-Fite CEO Dr. Pnina Fishman.
The inaugural Adenosine Pathway Targeted Cancer Immunotherapy
Summit is dedicated to optimizing the efficacy of adenosine pathway
targeted drugs, overcoming challenges of resistance and
immunosuppression, and supercharging therapeutics into the clinic.
The conference aims to maximize the clinical and commercial
opportunity of the adenosine pathway as a second-generation
immuno-oncology target.
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with
high affinity and selectivity to the A3 adenosine receptor (A3AR).
Namodenoson was evaluated in Phase II trials for two indications,
as a second line treatment for hepatocellular carcinoma, and as a
treatment for non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in
diseased cells whereas low expression is found in normal cells.
This differential effect accounts for the excellent safety profile
of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, and inflammatory disease. The
Company's lead drug candidate, Piclidenoson has completed
enrollment in a Phase III trial for psoriasis. Can-Fite's liver
drug, Namodenoson, is being evaluated in a Phase IIb trial for the
treatment of non-alcoholic steatohepatitis (NASH), and enrollment
is expected to commence in a Phase III trial for hepatocellular
carcinoma (HCC), the most common form of liver cancer. Namodenoson
has been granted Orphan Drug Designation in the U.S. and Europe and
Fast Track Designation as a second line treatment for HCC by the
U.S. Food and Drug Administration. Namodenoson has also shown proof
of concept to potentially treat other cancers including colon,
prostate, and melanoma. CF602, the Company's third drug candidate,
has shown efficacy in the treatment of erectile dysfunction. These
drugs have an excellent safety profile with experience in over
1,500 patients in clinical studies to date. For more information
please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. In addition, from time to
time, Can-Fite or its representatives have made or may make
forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters. These
forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or
with the approval of one of Can-Fite’s authorized executive
officers. Forward-looking statements relate to anticipated or
expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to
risks and uncertainties that could cause Can-Fite’s actual results
to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause
Can-Fite’s actual activities or results to differ materially from
the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking
statements include, but are not limited to: our history of losses
and needs for additional capital to fund our operations and our
inability to obtain additional capital on acceptable terms, or at
all; uncertainties of cash flows and inability to meet working
capital needs; the impact of the COVID-19 pandemic; the initiation,
timing, progress and results of our preclinical studies, clinical
trials and other product candidate development efforts; our ability
to advance our product candidates into clinical trials or to
successfully complete our preclinical studies or clinical trials;
our receipt of regulatory approvals for our product candidates, and
the timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain strategic
partnerships and other corporate collaborations; the implementation
of our business model and strategic plans for our business and
product candidates; the scope of protection we are able to
establish and maintain for intellectual property rights covering
our product candidates and our ability to operate our business
without infringing the intellectual property rights of others;
competitive companies, technologies and our industry; statements as
to the impact of the political and security situation in Israel on
our business; and risks and other risk factors detailed in
Can-Fite’s filings with the SEC and in its periodic filings with
the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced
by economic and other factors beyond its control. Can-Fite does not
undertake any obligation to publicly update these forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005267/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024